查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球免疫组织化学染色法(IHC) 市场：按产品和应用 - 预测（~2029 年）
市场调查报告书
商品编码
1545410

全球免疫组织化学染色法(IHC) 市场：按产品和应用 - 预测（~2029 年）

Immunohistochemistry (IHC) Market by Product (Antibodies (Type, Clonality), Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious, Autoimmune, Neurological), Research (Drug Development), Forensic) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 490 Pages | 订单完成后即时交付

价格

免疫组织化学染色法(IHC) 市场规模预计将从 2024 年的 37 亿美元成长到 2029 年的 52 亿美元，预测期内复合年增长率为 7.2%。

推动该市场成长的因素是老年人口中癌症患者的盛行率不断增加，以及 IHC 测试在癌症诊断和管理中的应用不断增加。此外，伴同性诊断 (CDx) 的发展及其与 IHC 技术的整合以开发个人化医疗，进一步支持了市场扩张。 IHC 在支持药物开发和疾病管理以改善患者治疗效果的应用，以及製药公司和学术机构之间的持续合作，也为参与者提供了成长机会。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2022-2029
单元 金额（美元）
部分 产品/应用程式/最终用户/地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

“在试剂中，组织染色预计将占据最大份额。”

2023 年，组织学染色细分市场在试剂子区隔中所占份额最大。在 IHC 中，组织染色用于可视化和区分组织样本内的特定细胞成分和结构。组织学染色也称为多重染色。该技术使用多个染色剂来检测一个组织切片内的多个目标。除了多重染色之外，组织学染色还透过区分正常和异常组织形态来用于癌症诊断。这些应用是推动 IHC 市场的主要因素。

“按使用情况来看，研究使用领域占据第二大份额。”

2023年，研究应用占据第二大份额。在研究中，IHC 技术用于抗癌药物开发和生物标记发现。确定特定蛋白质的表达和亚细胞位置可用于癌症和其他疾病研究。例如，IHC 广泛应用于癌症蛋白质体学研究，有助于发现新的药物标靶。研究中使用的自动化 IHC 平台可在玻片之间提供一致的染色，对于获得可靠的结果至关重要。 IHC 技术在胚胎学研究等发育研究中也很重要，它有助于可视化胚胎发育阶段的关键蛋白质。在干细胞研究中，IHC 用于监测分化和增殖标记物，从而深入了解干细胞行为。此外，在药物测试中，IHC 可以帮助评估新药对组织中特定蛋白质表现的影响。这些应用凸显了 IHC 在推动科学研究以及提高对各种疾病的理解和治疗方面所发挥的重要作用。

“亚太地区是成长最快的地区”

预计亚太地区在预测期内的 CARG 最高。该地区的高成长率归因于先进的 IHC 产品（例如检测和诊断套件）在研究和临床应用中的快速采用。除此因素外，人口老化、研究活动投资和资金筹措增加、可支配收入增加以及该地区学术和医疗基础设施的发展也成为该地区高成长率的关键驱动力。

本报告调查了全球免疫组织化学染色法(IHC) 市场，并提供了市场概况、对市场成长的各种影响因素的分析、技术和专利趋势、法律制度、市场规模趋势和预测以及各种其他资讯。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 影响客户业务的趋势/干扰
  • 价格分析
  • 技术分析
  • 专利分析
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 波特五力分析
  • 主要相关利益者和采购标准
  • 监管状况
  • 重大会议及活动
  • 投资金筹措场景
  • 人工智慧/生成人工智慧对免疫组织化学市场的影响

第六章免疫组织化学染色法(IHC) 市场：依报价细分

  • 抗体
    • 按类型）
    • 一抗
    • 二抗
    • 按克隆性
    • 单株抗体
    • 多株抗体
  • 试剂
    • 组织染色
    • 封闭血清和试剂
    • 显色基材
    • 固定试剂
    • 冲淡
    • 有机溶剂
    • 蛋白水解酶
    • 其他的
  • 装置
    • 玻片染色系统
    • 组织处理系统
    • 幻灯片扫描仪
    • 其他的
  • 套件
    • 人类免疫组化试剂套件
    • 动物免疫组化试剂套件
  • 软体

第 7 章免疫组织化学染色法(IHC) 市场：依应用分类

  • 诊断
    • 癌症
    • 感染疾病
    • 肾臟疾病
    • 自体免疫疾病
    • 神经系统疾病
    • 其他的
  • 研究
    • 药物开发/测试
    • 其他的
  • 法医学

第 8 章免疫组织化学染色法(IHC) 市场：依最终用户分类

  • 医院/诊断实验室
  • 学术研究所/CRO
  • 其他的

第 9 章免疫组织化学染色法(IHC) 市场：按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东
  • 非洲

第10章竞争格局

  • 主要企业/主要企业策略
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业
  • 企业评估矩阵：Start-Ups/中小企业
  • 企业价值评估及财务指标
  • 品牌/产品比较
  • 竞争场景

第十一章 公司简介

  • 主要企业
    • F. HOFFMANN-LA ROCHE LTD.
    • DANAHER CORPORATION
    • AGILENT TECHNOLOGIES, INC.
    • PHC HOLDINGS CORPORATION
    • THERMO FISHER SCIENTIFIC INC.
    • MERCK KGAA
    • BIO-RAD LABORATORIES, INC.
    • BIO-TECHNE
    • BECTON, DICKINSON AND COMPANY
    • TAKARA BIO INC.
    • ENZO BIOCHEM INC.
    • SINO BIOLOGICAL, INC.
    • SAKURA FINETEK JAPAN CO., LTD.
    • CELL SIGNALING TECHNOLOGY, INC.
    • BIO SB
    • MILTENYI BIOTEC
    • ORIGENE TECHNOLOGIES, INC.
  • 其他公司
    • EAGLEBIO
    • BIOCARE MEDICAL, LLC
    • ELABSCIENCE BIONOVATION INC.
    • BIOGENEX
    • DIAGNOSTIC BIOSYSTEMS INC.
    • HISTO-LINE LABORATORIES
    • ROCKLAND IMMUNOCHEMICALS, INC.
    • CANDOR BIOSCIENCE GMBH
    • GENEMED BIOTECHNOLOGIES, INC.

第十二章附录

Product Code: BT 4780

The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period of 2024 to 2029. Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology for the development of personalized medicine further support the expansion of the market. Application of IHC in supporting drug development and disease management to improve patient outcomes, along with ongoing research collaboration between pharmaceutical companies and academic institutes provide growth opportunities for players in the Immunohistochemistry Market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2022-2029
Units ConsideredValue (USD Billion)
SegmentsProduct, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

"Histological Stain is expected to account for the largest share of by reagents segment."

In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains

"Research applications segment accounted for the second-largest share of the application segment."

In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.

"Asia Pacific is the fastest-growing region in the immunohistochemistry market."

The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America- 7%, Middle East and Africa-3%

Prominent Players in the Immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).

Research Coverage:

This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)
  • Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the Immunohistochemistry market across varied regions.
  • Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 SEGMENTS COVERED
    • 1.4.2 YEARS CONSIDERED
    • 1.4.3 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 RESEARCH DESIGN
    • 2.1.2 SECONDARY DATA
      • 2.1.2.1 Secondary data sources
      • 2.1.2.2 Objectives of secondary research
    • 2.1.3 PRIMARY DATA
      • 2.1.3.1 Objectives of primary research
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH)
    • 2.2.2 INSIGHTS FROM PRIMARIES
  • 2.3 MARKET GROWTH FORECAST
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND COUNTRY (2023)
  • 4.3 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • 4.4 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023
  • 4.5 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of cancer and rising geriatric population
      • 5.2.1.2 Technological innovations and advancements in immunohistochemistry diagnostics
      • 5.2.1.3 Favorable reimbursement coverage for immunohistochemistry tests
      • 5.2.1.4 Growing focus on digital pathology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research
      • 5.2.2.2 Highly consolidated market
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing demand for precision/personalized medicines
      • 5.2.3.2 Increasing adoption of companion diagnostics
      • 5.2.3.3 Growth opportunities in emerging economies
      • 5.2.3.4 Integration of AI in immunohistochemistry
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables
      • 5.2.4.2 Lack of standardization
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
    • 5.4.2 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021-2023
    • 5.4.3 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021-2023
  • 5.5 TECHNOLOGY ANALYSIS
    • 5.5.1 KEY TECHNOLOGIES
      • 5.5.1.1 Automated immunohistochemistry systems
      • 5.5.1.2 Multiplex immunohistochemistry
    • 5.5.2 COMPLEMENTARY TECHNOLOGIES
      • 5.5.2.1 Chromogenic detection
      • 5.5.2.2 Fluorescent detection
    • 5.5.3 ADJACENT TECHNOLOGIES
      • 5.5.3.1 In situ hybridization
  • 5.6 PATENT ANALYSIS
    • 5.6.1 METHODOLOGY
    • 5.6.2 INNOVATION AND PATENT APPLICATIONS
    • 5.6.3 TOP PATENT APPLICANTS
  • 5.7 VALUE CHAIN ANALYSIS
    • 5.7.1 RESEARCH & DEVELOPMENT
    • 5.7.2 MANUFACTURING
    • 5.7.3 LOGISTICS AND POST-SALES
  • 5.8 SUPPLY CHAIN ANALYSIS
  • 5.9 ECOSYSTEM ANALYSIS
    • 5.9.1 ROLE OF RAW MATERIAL SUPPLIERS
    • 5.9.2 ROLE OF PRODUCT PROVIDERS
    • 5.9.3 ROLE OF END USERS
    • 5.9.4 ROLE OF REGULATORY AUTHORITIES
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.10.2 BARGAINING POWER OF SUPPLIERS
    • 5.10.3 BARGAINING POWER OF BUYERS
    • 5.10.4 THREAT OF SUBSTITUTES
    • 5.10.5 THREAT OF NEW ENTRANTS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.11.2 KEY BUYING CRITERIA
  • 5.12 REGULATORY LANDSCAPE
    • 5.12.1 REGULATORY ANALYSIS
      • 5.12.1.1 North America
        • 5.12.1.1.1 US
        • 5.12.1.1.2 Canada
      • 5.12.1.2 Europe
      • 5.12.1.3 Asia Pacific
        • 5.12.1.3.1 Japan
        • 5.12.1.3.2 China
        • 5.12.1.3.3 India
      • 5.12.1.4 Latin America
        • 5.12.1.4.1 Brazil
  • 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET

6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 ANTIBODIES
    • 6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
    • 6.2.2 PRIMARY ANTIBODIES
      • 6.2.2.1 Increasing adoption of targeted immunotherapy to drive segment
    • 6.2.3 SECONDARY ANTIBODIES
      • 6.2.3.1 Better signal amplification and easier manufacturing process to fuel segment growth
    • 6.2.4 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY
    • 6.2.5 MONOCLONAL ANTIBODIES
      • 6.2.5.1 Increased applications in cancer diagnostics to support market growth
    • 6.2.6 POLYCLONAL ANTIBODIES
      • 6.2.6.1 Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth
  • 6.3 REAGENTS
    • 6.3.1 HISTOLOGICAL STAINS
      • 6.3.1.1 Growing focus on cancer diagnostics and developmental research to drive segment
    • 6.3.2 BLOCKING SERA AND REAGENTS
      • 6.3.2.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption
    • 6.3.3 CHROMOGENIC SUBSTRATES
      • 6.3.3.1 Rapid detection and faster diagnosis to propel segment growth
    • 6.3.4 FIXATION REAGENTS
      • 6.3.4.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption
    • 6.3.5 DILUENTS
      • 6.3.5.1 Focus on reducing non-specific background staining during immunostaining to aid segment growth
    • 6.3.6 ORGANIC SOLVENTS
      • 6.3.6.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market
    • 6.3.7 PROTEOLYTIC ENZYMES
      • 6.3.7.1 Proteolytic enzymes to improve accessibility of target antibodies
    • 6.3.8 OTHER REAGENTS
  • 6.4 EQUIPMENT
    • 6.4.1 SLIDE-STAINING SYSTEMS
      • 6.4.1.1 Availability of technologically advanced slide-staining systems to fuel segment growth
    • 6.4.2 TISSUE PROCESSING SYSTEMS
      • 6.4.2.1 High equipment cost and need for extensive regulatory compliance to limit market
    • 6.4.3 SLIDE SCANNERS
      • 6.4.3.1 Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption
    • 6.4.4 OTHER EQUIPMENT
  • 6.5 KITS
    • 6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
      • 6.5.1.1 Increasing focus on cancer research to fuel segment growth
    • 6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
      • 6.5.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth
  • 6.6 SOFTWARE
    • 6.6.1 GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DIAGNOSTIC APPLICATIONS
    • 7.2.1 CANCER
      • 7.2.1.1 Increasing target population and rising adoption of targeted therapies to propel market growth
    • 7.2.2 INFECTIOUS DISEASES
      • 7.2.2.1 High prevalence of infectious diseases and need for early diagnosis to aid market growth
    • 7.2.3 NEPHROLOGICAL DISEASES
      • 7.2.3.1 Rising prevalence of renal transplant-associated conditions to drive market
    • 7.2.4 AUTOIMMUNE DISEASES
      • 7.2.4.1 Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth
    • 7.2.5 NEUROLOGICAL DISEASES
      • 7.2.5.1 Increasing global burden of neurological disorders to spur market growth
    • 7.2.6 OTHER DISEASES
  • 7.3 RESEARCH APPLICATIONS
    • 7.3.1 DRUG DEVELOPMENT AND TESTING
      • 7.3.1.1 Need for accurate and objective outcomes in drug testing to augment segment growth
    • 7.3.2 OTHER RESEARCH APPLICATIONS
  • 7.4 FORENSIC APPLICATIONS
    • 7.4.1 INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH

8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
    • 8.2.1 LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
  • 8.3 ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS
    • 8.3.1 GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH
  • 8.4 OTHER END USERS

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 9.2.2 US
      • 9.2.2.1 US to dominate North American immunohistochemistry market during forecast period
    • 9.2.3 CANADA
      • 9.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth
  • 9.3 EUROPE
    • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 9.3.2 GERMANY
      • 9.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market
    • 9.3.3 UK
      • 9.3.3.1 Rising prevalence of cancer and increasing government funding in health research to augment market growth
    • 9.3.4 FRANCE
      • 9.3.4.1 Increased research in cancer diagnosis and treatment to support market growth
    • 9.3.5 ITALY
      • 9.3.5.1 Advanced health infrastructure and high geriatric population to fuel market growth
    • 9.3.6 SPAIN
      • 9.3.6.1 Increased demand for personalized medicines to boost adoption of immunohistochemistry products
    • 9.3.7 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 9.4.2 CHINA
      • 9.4.2.1 Increasing focus on advanced cancer diagnostics to spur market growth
    • 9.4.3 JAPAN
      • 9.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth
    • 9.4.4 INDIA
      • 9.4.4.1 Need for high-end pathology and diagnostic services to propel market growth
    • 9.4.5 AUSTRALIA
      • 9.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth
    • 9.4.6 SOUTH KOREA
      • 9.4.6.1 Focus on precision healthcare and personalized medicines to drive market
    • 9.4.7 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 9.5.2 BRAZIL
      • 9.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth
    • 9.5.3 MEXICO
      • 9.5.3.1 Increasing research initiatives and rising cancer cases to drive market
    • 9.5.4 REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST
    • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 9.6.2 GCC COUNTRIES
      • 9.6.2.1 Saudi Arabia
        • 9.6.2.1.1 Growing cancer burden and increasing focus on research to augment market growth
      • 9.6.2.2 UAE
        • 9.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth
      • 9.6.2.3 Rest of GCC Countries
    • 9.6.3 REST OF MIDDLE EAST
  • 9.7 AFRICA
    • 9.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET
    • 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
  • 10.3 REVENUE ANALYSIS, 2021-2023
  • 10.4 MARKET SHARE ANALYSIS, 2023
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 10.5.5.1 Company footprint
      • 10.5.5.2 Offering footprint
      • 10.5.5.3 Application footprint
      • 10.5.5.4 Region footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 10.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 10.7.1 FINANCIAL METRICS
    • 10.7.2 COMPANY VALUATION
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    • 10.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 10.9.2 DEALS
    • 10.9.3 EXPANSIONS
    • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
    • 11.1.1 F. HOFFMANN-LA ROCHE LTD.
      • 11.1.1.1 Business overview
      • 11.1.1.2 Products/Solutions offered
      • 11.1.1.3 Recent developments
        • 11.1.1.3.1 Product launches and approvals
        • 11.1.1.3.2 Deals
      • 11.1.1.4 MnM view
        • 11.1.1.4.1 Key strengths
        • 11.1.1.4.2 Strategic choices
        • 11.1.1.4.3 Weaknesses and competitive threats
    • 11.1.2 DANAHER CORPORATION
      • 11.1.2.1 Business overview
      • 11.1.2.2 Products/Solutions offered
      • 11.1.2.3 Recent developments
        • 11.1.2.3.1 Product launches and approvals
        • 11.1.2.3.2 Deals
      • 11.1.2.4 MnM view
        • 11.1.2.4.1 Key strengths
        • 11.1.2.4.2 Strategic choices
        • 11.1.2.4.3 Weaknesses and competitive threats
    • 11.1.3 AGILENT TECHNOLOGIES, INC.
      • 11.1.3.1 Business overview
      • 11.1.3.2 Products/Solutions offered
      • 11.1.3.3 Recent developments
        • 11.1.3.3.1 Product launches and approvals
        • 11.1.3.3.2 Deals
        • 11.1.3.3.3 Expansions
      • 11.1.3.4 MnM view
        • 11.1.3.4.1 Key strengths
        • 11.1.3.4.2 Strategic choices
        • 11.1.3.4.3 Weaknesses and competitive threats
    • 11.1.4 PHC HOLDINGS CORPORATION
      • 11.1.4.1 Business overview
      • 11.1.4.2 Products/Solutions offered
      • 11.1.4.3 Recent developments
        • 11.1.4.3.1 Deals
        • 11.1.4.3.2 Other developments
      • 11.1.4.4 MnM view
        • 11.1.4.4.1 Key strengths
        • 11.1.4.4.2 Strategic choices
        • 11.1.4.4.3 Weaknesses and competitive threats
    • 11.1.5 THERMO FISHER SCIENTIFIC INC.
      • 11.1.5.1 Business overview
      • 11.1.5.2 Products/Solutions offered
    • 11.1.6 MERCK KGAA
      • 11.1.6.1 Business overview
      • 11.1.6.2 Products/Solutions offered
    • 11.1.7 BIO-RAD LABORATORIES, INC.
      • 11.1.7.1 Business overview
      • 11.1.7.2 Products/Solutions offered
    • 11.1.8 BIO-TECHNE
      • 11.1.8.1 Business overview
      • 11.1.8.2 Products/Solutions offered
      • 11.1.8.3 Recent developments
        • 11.1.8.3.1 Deals
        • 11.1.8.3.2 Expansions
        • 11.1.8.3.3 Other developments
    • 11.1.9 BECTON, DICKINSON AND COMPANY
      • 11.1.9.1 Business overview
      • 11.1.9.2 Products/Solutions offered
      • 11.1.9.3 Recent developments
        • 11.1.9.3.1 Expansions
    • 11.1.10 TAKARA BIO INC.
      • 11.1.10.1 Business overview
      • 11.1.10.2 Products/Solutions offered
    • 11.1.11 ENZO BIOCHEM INC.
      • 11.1.11.1 Business overview
      • 11.1.11.2 Products/Solutions offered
      • 11.1.11.3 Recent developments
        • 11.1.11.3.1 Expansions
    • 11.1.12 SINO BIOLOGICAL, INC.
      • 11.1.12.1 Business overview
      • 11.1.12.2 Products/Solutions offered
      • 11.1.12.3 Recent developments
        • 11.1.12.3.1 Expansions
    • 11.1.13 SAKURA FINETEK JAPAN CO., LTD.
      • 11.1.13.1 Business overview
      • 11.1.13.2 Products/Solutions offered
      • 11.1.13.3 Recent developments
        • 11.1.13.3.1 Product launches
        • 11.1.13.3.2 Deals
    • 11.1.14 CELL SIGNALING TECHNOLOGY, INC.
      • 11.1.14.1 Business overview
      • 11.1.14.2 Products/Solutions offered
      • 11.1.14.3 Recent developments
        • 11.1.14.3.1 Deals
    • 11.1.15 BIO SB
      • 11.1.15.1 Business overview
      • 11.1.15.2 Products/Solutions offered
      • 11.1.15.3 Recent developments
        • 11.1.15.3.1 Product launches
    • 11.1.16 MILTENYI BIOTEC
      • 11.1.16.1 Business overview
      • 11.1.16.2 Products/Solutions offered
    • 11.1.17 ORIGENE TECHNOLOGIES, INC.
      • 11.1.17.1 Business overview
      • 11.1.17.2 Products/Solutions offered
  • 11.2 OTHER PLAYERS
    • 11.2.1 EAGLEBIO
    • 11.2.2 BIOCARE MEDICAL, LLC
    • 11.2.3 ELABSCIENCE BIONOVATION INC.
    • 11.2.4 BIOGENEX
    • 11.2.5 DIAGNOSTIC BIOSYSTEMS INC.
    • 11.2.6 HISTO-LINE LABORATORIES
    • 11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
    • 11.2.8 CANDOR BIOSCIENCE GMBH
    • 11.2.9 GENEMED BIOTECHNOLOGIES, INC.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS
  • TABLE 3 ESTIMATED NUMBER OF NEW CASES, BY REGION, 2022-2045 (THOUSAND)
  • TABLE 4 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION, 2022-2050
  • TABLE 5 CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES
  • TABLE 6 MAJOR ACQUISITIONS IN IMMUNOHISTOCHEMISTRY MARKET, 2020-2023
  • TABLE 7 AVERAGE SELLING PRICE FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
  • TABLE 8 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021-2023 (USD)
  • TABLE 9 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021-2023 (USD)
  • TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
  • TABLE 11 TOP 20 PATENT OWNERS IN IMMUNOHISTOCHEMISTRY MARKET, 2014-2024
  • TABLE 12 INDICATIVE LIST OF PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2022-2024
  • TABLE 13 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF RAW MATERIAL SUPPLIERS
  • TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF PRODUCT PROVIDERS
  • TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF END USERS
  • TABLE 16 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF REGULATORY AUTHORITIES
  • TABLE 17 IMMUNOHISTOCHEMISTRY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 18 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY END USER
  • TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
  • TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
  • TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS
  • TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 24 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
  • TABLE 25 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 26 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 34 PRIMARY ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 35 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 SECONDARY ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 42 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 49 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 64 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 HISTOLOGICAL STAINS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 EUROPE: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 LATIN AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 MIDDLE EAST: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 GCC COUNTRIES: HISTOLOGICAL STAINS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 BLOCKING SERA AND REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 EUROPE: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 MIDDLE EAST: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 GCC COUNTRIES: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 FIXATION REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 MIDDLE EAST: FIXATION REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 DILUENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 EUROPE: DILUENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 MIDDLE EAST: DILUENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 ORGANIC SOLVENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 107 NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 PROTEOLYTIC ENZYMES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 OTHER REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 MIDDLE EAST: OTHER REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 128 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 129 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 IMMUNOHISTOCHEMISTRY SLIDE-STAINING SYSTEMS MARKET, BY VOLUME, 2022-2029 (UNITS)
  • TABLE 136 SLIDE-STAINING SYSTEMS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 137 NORTH AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 EUROPE: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 LATIN AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 141 MIDDLE EAST: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 GCC COUNTRIES: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 TISSUE PROCESSING SYSTEMS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 144 NORTH AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 EUROPE: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 148 MIDDLE EAST: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 GCC COUNTRIES: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 150 SLIDE SCANNERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 152 EUROPE: SLIDE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: SLIDE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 MIDDLE EAST: SLIDE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: SLIDE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 157 OTHER EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 158 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 162 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 164 IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 165 IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 166 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 169 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 172 HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 174 EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 177 MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 178 GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 179 ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 181 EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 183 LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 184 MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 186 IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 188 EUROPE: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 190 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 191 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 193 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 194 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 195 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 196 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 197 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 200 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 201 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 202 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
  • TABLE 203 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 204 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 207 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 208 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 209 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 210 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
  • TABLE 211 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 212 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 215 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 216 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 217 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 218 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 219 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 220 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 222 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 223 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 224 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 225 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 226 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 227 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 230 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 231 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 232 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR NEUROLOGICAL DISEASES
  • TABLE 233 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 234 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 235 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: I IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 237 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 238 MIDDLE EAST IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 239 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 240 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 241 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 242 EUROPE IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 243 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 245 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 246 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 247 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 248 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 249 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 250 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 251 ASIA PACIFIC IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 252 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 253 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 254 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 255 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 256 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 257 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 259 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 260 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 261 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 262 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 263 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 264 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 266 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 267 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 268 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 269 IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 270 NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 271 EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 273 LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 274 MIDDLE EAST: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 275 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 276 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 277 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 278 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 279 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 281 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 282 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 283 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 284 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 285 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 286 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 288 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 289 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 291 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 292 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 293 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 296 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 298 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 299 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 300 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 301 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 303 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 306 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 307 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 310 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 311 US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 312 US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 313 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 314 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 315 US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 316 US: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 318 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 319 US: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 320 US: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 321 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 322 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 323 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 324 CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 325 CANADA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 326 CANADA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 327 CANADA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 328 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 329 CANADA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 330 CANADA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 331 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 332 EUROPE: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 333 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 334 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 335 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 336 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 337 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 338 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 340 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 341 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 342 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 343 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 344 EUROPE: KEY MACROINDICATORS
  • TABLE 345 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 346 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 347 GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 348 GERMANY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 349 GERMANY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 350 GERMANY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 351 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 352 GERMANY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 353 GERMANY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 354 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 355 UK: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 356 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 357 UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 358 UK: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 359 UK: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 360 UK: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 361 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 362 UK: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 363 UK: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 364 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 365 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 366 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 367 FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 368 FRANCE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 369 FRANCE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 370 FRANCE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 372 FRANCE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 373 FRANCE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 375 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 376 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 377 ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 378 ITALY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 379 ITALY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 380 ITALY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 381 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 382 ITALY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 383 ITALY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 384 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 385 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 386 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 387 SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 388 SPAIN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 389 SPAIN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 390 SPAIN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 391 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 392 SPAIN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 393 SPAIN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 394 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 395 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 396 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 397 REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 398 REST OF EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 399 REST OF EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 400 REST OF EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 401 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 402 REST OF EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 403 REST OF EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 404 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 405 ASIA PACIFIC: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 406 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 407 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 408 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 409 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 410 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 411 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 412 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 413 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 414 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 415 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 416 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 417 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 418 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 419 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 420 CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 421 CHINA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 422 CHINA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 423 CHINA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 424 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 425 CHINA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 426 CHINA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 427 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 428 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 429 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 430 JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 431 JAPAN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 432 JAPAN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 433 JAPAN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 434 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 435 JAPAN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 436 JAPAN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 437 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 438 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 439 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 440 INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 441 INDIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 442 INDIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 443 INDIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 444 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 445 INDIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 446 INDIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 447 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 448 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 449 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 450 AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 451 AUSTRALIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 452 AUSTRALIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 453 AUSTRALIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 454 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 455 AUSTRALIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 456 AUSTRALIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 457 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 458 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 459 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 460 SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 461 SOUTH KOREA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 462 SOUTH KOREA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 463 SOUTH KOREA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 464 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 465 SOUTH KOREA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 466 SOUTH KOREA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 467 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 468 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 469 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 470 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 471 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 472 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 473 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 474 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 475 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 476 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 477 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 478 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 479 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 480 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 481 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 482 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 483 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 484 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 485 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 486 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 487 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 488 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 489 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 490 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 491 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 492 BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 493 BRAZIL: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 494 BRAZIL: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 495 BRAZIL: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 496 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 497 BRAZIL: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 498 BRAZIL: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 499 BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 500 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 501 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 502 MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 503 MEXICO: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 504 MEXICO: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 505 MEXICO: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 506 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 507 MEXICO: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 508 MEXICO: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 509 MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 510 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 511 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 512 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 513 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 514 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 515 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 516 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 517 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 518 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 519 REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 520 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 521 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 522 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 523 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 524 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 525 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 526 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 527 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 528 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 529 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 530 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 531 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 532 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 533 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 534 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 535 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 536 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 537 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 538 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 539 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 540 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 541 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 542 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 543 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 544 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 545 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 546 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 547 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 548 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 549 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 550 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 551 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 552 SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 553 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 554 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 555 UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 556 UAE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 557 UAE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 558 UAE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 559 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 560 UAE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 561 UAE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 562 UAE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 563 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 564 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 565 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 566 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 567 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 568 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 569 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 570 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 571 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 572 REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 573 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 574 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 575 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 576 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 577 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 578 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 579 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 580 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 581 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 582 REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 583 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 584 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 585 AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022-2029 (USD MILLION)
  • TABLE 586 AFRICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 587 AFRICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 588 AFRICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 589 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 590 AFRICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 591 AFRICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 592 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 593 AFRICA: KEY MACROINDICATORS
  • TABLE 594 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
  • TABLE 595 IMMUNOHISTOCHEMISTRY MARKET: DEGREE OF COMPETITION
  • TABLE 596 IMMUNOHISTOCHEMISTRY MARKET: OFFERING FOOTPRINT
  • TABLE 597 IMMUNOHISTOCHEMISTRY MARKET: APPLICATION FOOTPRINT
  • TABLE 598 IMMUNOHISTOCHEMISTRY MARKET: REGION FOOTPRINT
  • TABLE 599 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 600 IMMUNOHISTOCHEMISTRY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 601 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2024
  • TABLE 602 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2021-JULY 2024
  • TABLE 603 IMMUNOHISTOCHEMISTRY MARKET: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 604 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JULY 2024
  • TABLE 605 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 606 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 607 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2024
  • TABLE 608 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 609 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 610 DANAHER CORPORATION: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 611 DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2024
  • TABLE 612 DANAHER CORPORATION: DEALS, JANUARY 2021-JULY 2024
  • TABLE 613 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 614 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 615 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2024
  • TABLE 616 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 617 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 618 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 619 PHC HOLDINGS CORPORATION: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 620 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2021- JULY 2024
  • TABLE 621 PHC HOLDINGS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021-JULY 2024
  • TABLE 622 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 623 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 624 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 625 MERCK KGAA: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 626 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 627 BIO-RAD LABORATORIES, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 628 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 629 BIO-TECHNE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 630 BIO-TECHNE: DEALS, JANUARY 2021- JULY 2024
  • TABLE 631 BIO-TECHNE: EXPANSIONS, JANUARY 2021- JULY 2024
  • TABLE 632 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021- JULY 2024
  • TABLE 633 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 634 BECTON, DICKINSON AND COMPANY: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 635 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2021- JULY 2024
  • TABLE 636 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 637 TAKARA BIO INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 638 ENZO BIOCHEM INC.: COMPANY OVERVIEW
  • TABLE 639 ENZO BIOCHEM INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 640 ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 641 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW
  • TABLE 642 SINO BIOLOGICAL, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 643 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 644 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW
  • TABLE 645 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 646 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
  • TABLE 647 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 648 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 649 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 650 CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 651 BIO SB: COMPANY OVERVIEW
  • TABLE 652 BIO SB: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 653 BIO SB: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
  • TABLE 654 MILTENYI BIOTEC: COMPANY OVERVIEW
  • TABLE 655 MILTENYI BIOTEC: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 656 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 657 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 658 EAGLEBIO: COMPANY OVERVIEW
  • TABLE 659 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW
  • TABLE 660 ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW
  • TABLE 661 BIOGENEX: COMPANY OVERVIEW
  • TABLE 662 DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW
  • TABLE 663 HISTO-LINE LABORATORIES: COMPANY OVERVIEW
  • TABLE 664 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW
  • TABLE 665 CANDOR BIOSCIENCE GMBH: COMPANY OVERVIEW
  • TABLE 666 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET: SEGMENTS & REGIONS COVERED
  • FIGURE 2 IMMUNOHISTOCHEMISTRY MARKET: YEARS CONSIDERED
  • FIGURE 3 IMMUNOHISTOCHEMISTRY MARKET: RESEARCH DESIGN
  • FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2023)
  • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTION, 2024-2029
  • FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT
  • FIGURE 17 GROWING PREVALENCE OF CANCER AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
  • FIGURE 18 US AND DIAGNOSTIC APPLICATIONS DOMINATED NORTH AMERICAN MARKET IN 2023
  • FIGURE 19 ANTIBODIES TO DOMINATE IMMUNOHISTOCHEMISTRY MARKET IN 2029
  • FIGURE 20 HOSPITALS AND DIAGNOSTIC LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 22 IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 RATE OF CANCER INCIDENCE, BY REGION AND CANCER TYPE (2022)
  • FIGURE 24 SHARE OF PERSONALIZED MEDICINES APPROVED BY FDA (2015-2023)
  • FIGURE 25 IMMUNOHISTOCHEMISTRY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 26 AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021-2023
  • FIGURE 27 AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY CONSUMABLES, 2021-2023
  • FIGURE 28 TOTAL NUMBER OF PATENTS GRANTED, 2014-2024
  • FIGURE 29 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
  • FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 31 IMMUNOHISTOCHEMISTRY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 32 IMMUNOHISTOCHEMISTRY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 33 IMMUNOHISTOCHEMISTRY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS
  • FIGURE 35 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 36 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 37 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 38 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 39 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 40 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 41 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 42 IMMUNOHISTOCHEMISTRY MARKET: IMPACT OF AI/GEN AI
  • FIGURE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023)
  • FIGURE 44 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023)
  • FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2021-2023)
  • FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2023)
  • FIGURE 47 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 48 IMMUNOHISTOCHEMISTRY MARKET: COMPANY FOOTPRINT
  • FIGURE 49 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 50 PRICE-TO-EARNINGS(P/E) RATIO OF KEY VENDORS
  • FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 52 IMMUNOHISTOCHEMISTRY MARKET: BRAND/COMPARISON
  • FIGURE 53 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 57 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 60 BIO-TECHNE: COMPANY SNAPSHOT (2023)
  • FIGURE 61 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 62 TAKARA BIO INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 63 ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2023)